SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors speculate on a major partnership announcement and await potential regulatory progress, with community members actively discussing its integration into the Stellar ecosystem and potential future collaborations with Ripple. While some participants express caution regarding market volatility and historical performance, many remain focused on the project's long-term utility as a real-time payroll infrastructure.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is rallying around the project as it approaches two years of continuous operation on the Solana blockchain. Investors are actively sharing swap instructions and engaging in lighthearted community banter to maintain visibility and momentum.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is capturing significant community attention driven by its low circulating supply and small market capitalization, which many investors believe positions the token for potential parabolic growth. Supporters are actively discussing the asset as an undervalued gem, with many calling for increased volume to trigger a breakout to higher price levels.

Dunald Dump

DUNALD is capturing market attention as traders actively discuss its potential for rapid growth and coordinate its visibility alongside other meme-themed assets. The community remains divided, balancing enthusiastic calls to participate in the momentum against skepticism regarding the underlying value of the project.

Sound Group, Inc. is a global, AI-powered audio company on a mission to help people connect better and live happier. Leveraging its voice AI technologies and deep expertise in audio interaction, Sound Group is building a diverse ecosystem of intelligent audio products that cater to a global user base. By integrating technology, innovative products, and real-world data within a user-centric ecosystem, Sound Group generates a powerful growth flywheel that is driving continuous innovation and accelerating global expansion. The company was founded by Jinnan Lai and Ning Ding in 2010 and is headquartered in Singapore.

Sound Group Inc - ADR

Sound Group Inc

Sound Group Inc. (SOGP) is seeing heightened community discussion as traders analyze its financials, specifically highlighting a 'negative working capital' strategy where the company collects cash upfront while delaying vendor payments. Investors are actively debating the sustainability of this model and the potential impact of a special dividend on share volatility while monitoring for signs of market maker manipulation.

Maul Coin

Maul Coin is generating buzz among retail traders who are actively coordinating social media raids and burning supply to drive organic growth. The community is focused on building long-term momentum and overcoming initial skepticism as they push for increased visibility on major tracking platforms.

Nutanix, Inc. engages in the provision of a cloud platform leveraging web-scale engineering and consumer-grade design. It operates through the following geographic segments: United States, Europe, the Middle East, Africa, Asia Pacific, and Other Americas. The firm also provides software solutions and cloud services to customers' enterprise infrastructure. The company was founded by Dheeraj Pandey, Ajeet Singh, and Mohit Aron in 2009 and is headquartered in San Jose, CA.

Nutanix Inc - Ordinary Shares - Class A

Nutanix Inc 

Nutanix is surging following a strong quarterly earnings report that exceeded top and bottom-line expectations, coupled with a strategic multi-year partnership and equity investment from AMD to develop AI infrastructure. Investors are actively debating the stock's future trajectory, weighing the excitement around the AI collaboration against the company's slightly lowered guidance and ongoing supply chain considerations.

Suncor Energy, Inc. is an integrated energy company, which engages in the development of petroleum resource basins. It operates through the following segments: Oil Sands, Exploration and Production, Refining and Marketing, and Corporate and Eliminations. The Oil Sands segment includes oil sands operations which includes mining, extraction, upgrading, in situ and related logistics, blending and storage assets. The Exploration and Production segment includes offshore operations off the east coast of Canada and onshore assets in Libya and Syria, and marketing and risk management of crude oil. The Refining and Marketing segment focuses on refining and supply operations refine crude oil and intermediate feedstock into a wide range of petroleum and petrochemical products, and marketing of refined petroleum products to retail customers across Canada and US. The Corporate and Eliminations segment includes activities not directly attributable to any other operating segment. The company was founded in 1917 and is headquartered in Calgary, Canada.

Suncor Energy, Inc.

Suncor Energy is trending due to the completion of its strategic acquisition of TotalEnergies' remaining stake in the Fort Hills oil-sands mine, a move aimed at bolstering long-term production and reserves. Investors are actively discussing the company's operational performance, its ability to navigate volatile crude prices, and ongoing expectations for enhanced shareholder returns through disciplined capital allocation and potential dividend growth.

The ArcBlock project was created to create the first Blockchain ecosystem in the world. Develop and develop decentralized applications (DApp) according to objectives. ArcBlock, one of the ICO projects emerging in early 2018. Just launched on 3/1/2018, ArcBlock has quickly attracted the attention of technology as well as investors. ArcBlock brings great technological advancements that will open the third generation of blockchain applications.  Arcblock work by bridging the gap between different blockchains and their respective ecosystems has not been easy. There are some solutions which attempt to solve this problem, but it is evident there is plenty of room for competition in this regard. Building an open chain access layer capable of spanning multiple new and existing blockchains is a very interesting business model.  Building a new ecosystem meant to connect various chains will not be easy. As of right now, the team has completed its token sale, and the first public release candidate for the Open Chain Access Protocol will be released in Q3. Early 2019 will herald the introduction of more technical features and an Ethereum Blocklet prototype.

ArcBlock (ABT) is trending amid intense debate over its price action, with bullish investors highlighting recent exchange listings and the release of Arcsphere as catalysts for a potential rally. Conversely, skeptical community members frequently label the token as a "pump and dump" scheme, citing frustration over long-term underperformance and a perceived lack of meaningful partnership news despite active social media promotion.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as the community highlights its pivotal role in the real-world asset (RWA) sector, driven by key partnerships with major financial institutions like BlackRock and Franklin Templeton. While many investors remain bullish on its long-term institutional adoption and tokenization potential, others are actively debating the impact of upcoming token unlocks and the current price stagnation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.</li><li>Last week, Outlook Therapeutics announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.</li><li>In December 2025, the FDA issued a Complete Response Letter for ONS-5010 / LYTENAVA, saying it could not approve the treatment in its current form for wet AMD.</li></ul>Outlook Therapeutics Inc. (OTLK) shares plunged 32% in Tuesday’s pre-market trade after the company announced a proposed public offering of its common stock and accompanying warrants.Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25. The company said it expects aggregate gross proceeds of $5 million and that the offering is expected to close on Wednesday, March 25, 2026.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/OTLK">Outlook Therapeutics</a> trended in the ‘extremely bearish’ territory, with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">Why Did Outlook Therapeutics Announce The Offering?</h2>Outlook Therapeutics stated that it intends to use the proceeds of the stock offering to meet its working capital requirements as well as other general corporate needs.Last week, the company announced a new $18.4 million non-convertible unsecured note financing, stating that it will use a portion of the net proceeds to pay down an existing note.Earlier this month, Outlook Therapeutics provided an update with respect to a meeting with the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Application for its treatment of wet age-related macular degeneration (wet AMD).In December 2025, the company said that the FDA issued a Complete Response Letter for its investigational treatment, ONS-5010 / LYTENAVA (bevacizumab-vikg), stating that it cannot approve the application in its present form for the treatment of wet AMD.The company said that if the FDA approves it, bevacizumab-vikg has the potential to be the first ophthalmic formulation of bevacizumab-vikg approved by the regulator for use in ophthalmology.Bevacizumab-vikg is a lab-made antibody that targets a protein called VEGF, which helps blood vessels grow. By blocking VEGF from binding to its receptors on blood vessel cells, the drug prevents the formation of new blood vessels.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Outlook Therapeutics’ proposed offering was&nbsp;criticized&nbsp;by a user on the platform, who called out the company for not giving a roadmap on how it intends to use the money, other than meeting its working capital and general corporate needs.<stembedurl>https://stocktwits.com/HarveySpecter20/message/648356634</stembedurl>Another user highlighted the lack of data on the uptake of the investigational treatment from patients.<stembedurl>https://stocktwits.com/updownsides/message/648355300</stembedurl><a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> is down 80% year-to-date and 79% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 16% over the past 12 months, while the iShares Micro-Cap ETF (IWC) is up 38%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fidelity-backs-elon-musk-tesla-spacex-terafab-project-datacenters-in-space/cZ3mK7PRI0u">Elon Musk's Joint Tesla, SpaceX Terafab Project Makes A 'Ton Of Sense', Says Investor Fidelity: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Is OTLK Stock Falling Today?

Outlook Therapeutics announced the pricing of the public offering, stating that each share of common stock and the accompanying warrant are being sold at a combined price of $0.25.

Equity

Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates

Oncobiologics (OTLK) delivered earnings and revenue surprises of -26.95% and -131.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Outlook Therapeutics Earnings Report: Q1 Overview

OTLK Stock Crashes 67% in a Week: Here's What You Need to Know

Outlook Therapeutics stock plunges 67% in a week after the FDA issues a third CRL rejecting its ONS-5010 BLA for wet AMD, again seeking confirmatory data.

Wall Street Zen Downgrades Oncobiologics (NASDAQ:OTLK) to Sell

Wall Street Zen downgraded Oncobiologics from a "hold" rating to a "sell" rating in a research report on Saturday...

Futures Blast Off On First Day Of 2026 With Europe, Asia At Records

Futures Blast Off On First Day Of 2026 With Europe, Asia At Records Stocks are set to break a four-day losing streak as markets start the new year with a bang across global markets, boosted by the...

<ul class="summary-bullets"><li>The FDA said it cannot approve the application in its present form for the treatment of wet age-related macular degeneration.</li><li>This marked the second rejection for Outlook’s drug for wet AMD treatment in less than six months.</li><li>The CEO said, “We are disappointed and disagree with this decision.</li></ul>Shares of Outlook Therapeutics (<a href="https://stocktwits.com/symbol/OTLK">OTLK</a>) slumped more than 60% on Friday after it failed to secure U.S. Food and Drug Administration approval for its drug Lytenava, which is intended to treat wet age-related macular degeneration (wet AMD), a chronic eye disorder.This marked the second rejection for Outlook’s drug for wet AMD treatment in less than six months. In August, the FDA declined to approve the drug, citing insufficient evidence of effectiveness, and recommended that the company submit additional data to support its application.In the Complete Response Letter (CRL), the FDA noted that the additional mechanistic and natural history data provided in the biologics license application (BLA) resubmission do not alter the previous review conclusion, adding that the FDA cannot approve the application in its present form for the treatment of wet age-related macular degeneration.“We are disappointed and disagree with this decision, but we remain fully committed to taking all necessary steps to receive approval in the United States,” Bob Jahr, Chief Executive Officer of Outlook Therapeutics, said in a statement.Lytenava has been granted marketing authorization by the European Commission in the EU and marketing authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of wet AMD.Age-related macular degeneration causes damage to the macula, a small area near the center of the retina, which is the part of the eye responsible for sharp, central vision. It is common among people aged 50 and older.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around OTLK trended in ‘extremely bullish’ territory amid ‘extremely high’ message volumes.<figure class="image"><img style="aspect-ratio:636/66;" src="https://news.stocktwits-cdn.com/otlk_3_PNG_39a4a7c8e1.webp" alt="Retail sentiment around OTLK trended in ‘extremely bullish’ territory amid ‘extremely high’ message volumes." width="636" height="66"></figure>However, the latest blow from the FDA has disappointed retail traders, with one user saying, “Even if they have money, they have proven approval is beyond their abilities.”<figure class="image"><img style="aspect-ratio:651/132;" src="https://news.stocktwits-cdn.com/OTLK_USER_1_PNG_ebd1b97a3d.webp" alt="latest blow from the FDA has disappointed retail traders, with one user saying, “Even if they have money, they have proven approval is beyond their abilities.”" width="651" height="132"></figure> The FDA disapproval prompted users to believe the company would do cost-cutting. With one user saying to expect the next PR to be cost-cutting and layoffs, followed by dilution, and yet another reverse split.<img src="https://news.stocktwits-cdn.com/otlk_4_PNG_f4b526073b.webp" alt="otlk 4.PNG">Shares of Outlook Therapeutics were down nearly 17% in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Outlook Therapeutics Tanks Over 60% On Another FDA Blow – Here’s How Retail Is Reacting 

OTLK Stock - The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.

A Second FDA Rejection Sparked A Rout In Outlook Therapeutics Shares 

The U.S. health regulatory agency, the FDA, rejected Outlook Therapeutics’ application for approval of its drug Lytenava, which is intended to treat wet AMD.

Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again

Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.read more...

Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Hold" from Analysts

Oncobiologics, Inc. (NASDAQ:OTLK - Get Free Report) has been assigned an average rating of "Hold" from the six analysts that are covering the firm, Marketbeat reports. One equities research analyst...

This account has been verified as an official OTLK representative.

Verified Account

Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Outlook Therapeutics Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.12	--	--	N/A
Q1 '26	-$0.23	-$0.22	2.94%	BEAT
Q4 '25	-$0.23	-$0.06	74.29%	BEAT
Q3 '25	-$0.35	-$0.44	-24.82%	MISSED
Q2 '25	-$0.54	-$0.40	26.31%	BEAT

OTLK
Outlook Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest OTLK News

OTLKOutlook Therapeutics Inc